HQY

HealthEquity's 15.7% three-month rally is backed by rising HSA scale, stronger margins and higher guidance, though key risks remain.

HealthEquity (NASDAQ:HQY) posted second-quarter fiscal 2027 results on August 27, which pushed revenue growth to 8% year over year, up from the 7% pace set over the first half of the year, a rare acceleration for a company already sitting on 10.7 million health savings accounts/HSAs. Adjusted EBITDA jumped 11% to $167 million, translating into […]

Record profitability and accelerated invested asset growth signal durability.

Deutsche Bank analyst George Hill maintains HealthEquity (NASDAQ:HQY) with a Buy and raises the price target from $135 to $142.

Sales and earnings beats in fiscal Q2 weren't enough to satisfy investors.

HealthEquity (HQY) is back in focus after reporting second quarter results on 27 August 2026, along with higher full year guidance, a completed share repurchase tranche and a new employee stock plan related shelf registration. Despite the strong Q2 update and raised full year guidance, HealthEquity’s share price has pulled back sharply in the very short term, with a 1 day share price return of dow

HealthEquity stock has delivered a solid 5 year gain, yet current valuation checks send a mixed message as the Discounted Cash Flow (DCF) intrinsic value estimate points to a sizeable discount while market based multiples look stretched. Recent share price weakness adds another layer, since the broader value score does not clearly classify the stock as either cheap or expensive. HealthEquity has r

BTIG analyst David Larsen reiterates HealthEquity (NASDAQ:HQY) with a Buy and maintains $115 price target.